Compugen Ltd. (USA) (NASDAQ:CGEN)

CAPS Rating: 5 out of 5

A biotechnology discovery company focused on discovering and licensing of product candidates to the drug and diagnostic industry.

Recs

0
Player Avatar creelon (< 20) Submitted: 1/27/2013 3:11:00 PM : Outperform Start Price: $5.61 CGEN Score: +19.98

new silicon-driven system for drug discovery. Focused on high return sectors.

Featured Broker Partners


Advertisement